An implantable scaffold and magnetic probes capture circulating tumor cells directly in the bloodstream, eliminating over 90% ...

Over the past decade, circulating tumor DNA (ctDNA) has emerged as one of the most transformative biomarkers in oncology, offering unprecedented ...

Low baseline ctDNA levels in advanced breast cancer patients predict better response to targeted therapy and longer ...

A personalized blood test known as a circulating tumor DNA (ctDNA) test—which detects tiny fragments of cancer DNA ...

Millions of people worldwide are diagnosed with cancer every year. In advanced tumor diseases, cancer cells detach from the ...

A team led by investigators at the Mass General Brigham Cancer Institute has discovered that a particular marker on tumor cells circulating in the blood indicates whether a patient with lung cancer ...

The TellDx CTC iChip platform enables high-efficiency isolation of intact circulating tumor cells without reliance on cell size or epithelial markers. This unbiased approach is particularly well ...

Of all the types of breast cancer, triple negative breast cancer (TNBC) is the most aggressive and lacks specific therapies.

A personalized blood test known as a circulating tumor DNA (ctDNA) test—which detects tiny fragments of cancer DNA ...

Guardant’s test analyzes circulating tumor DNA that is then used to identify patients with BRAF V600E-mutant metastatic colorectal cancer who may benefit from treatment with the Braftovi combo therapy ...

The U.S. Food and Drug Administration (FDA) has approved Guardant360 CDx as a companion diagnostic to identify patients with ...

Tumor cells leaving the original tissue and settling in distant organs of the body is referred to as metastasis of the primary tumor. Since in most cases it is not the primary tumor but metastases ...